Abstract The nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase Sirtuin 2 (SIRT2) plays a regulatory function in diverse cellular processes and has been linked to aging and the development of neurodegenerative and cancerous diseases. Consequently, targeting SIRT2 has emerged as a promising anticancer therapeutic strategy; however, currently available SIRT2 inhibitors and modulators often exhibit limited potency and suboptimal selectivity.
Peter Sidhom
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Peter
Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack